Get the latest news, insights, and market updates on RAPP (Rapport Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected in the first half of 2027Strong balance sheet, bolstered by approximately $269.4 million in net proceeds from recent public offering Ended the quarter with $513.0 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund ope Nov 6, 2025 - $RAPP
Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: Stifel 2025 Healthcare Conference (New York City, NY) – fireside chat on Thursday, November 13, 202 Nov 5, 2025 - $RAPP
Why Rapport Therapeutics (RAPP) Is Up 6.3% After Positive Phase 2a Epilepsy Drug Results and Analyst Optimism
Earlier this week, Rapport Therapeutics announced positive Phase 2a trial results for RAP-219 in refractory focal epilepsy, demonstrating best-in-class efficacy and good tolerability. This milestone attracted renewed analyst optimism, highlighting the significant commercial potential for RAP-219 in central nervous system disorders. We'll examine how the robust clinical data for RAP-219 positions Rapport Therapeutics to reshape its investment narrative around breakthrough treatments. Uncover... Oct 2, 2025 - $RAPP
JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a price target of $77, implying a potential surge of about 174%. This announcement follows the publication of “stellar results” from the Phase 2a trial […] Sep 30, 2025 - $RAPP
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor conference. TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (virtual) – firesi Sep 11, 2025 - $RAPP
Rapport Announces Pricing of Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at a public offering price of $26.00 per share. All of the shares in the offering are being Sep 10, 2025 - $RAPP
Top Midday Gainers
Eightco Holdings (OCTO) said Monday it priced a private placement for 171.2 million shares at $1.46 Sep 8, 2025 - $RAPP
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple